Almonty Q3 2026 Results Fail to Provide Key Sangdong Ramp Evidence

What happened

Almonty Industries reported third quarter 2026 financial results on November 12, 2026, but the excerpted release lacks specific revenue, earnings, and cash flow figures. Based on the prior quarter and management disclosures, the company likely continued to generate losses as Sangdong remained in ramp-up without confirmed first customer shipment. The critical milestones identified in the DeepValue master report—disclosed first delivery, recovery rates, and quarterly throughput—have not been evidenced in the announcement's summary. Financing risk remains elevated as the KfW-linked senior secured term loan enters amortization, and the US$800 million convertible notes add future dilution. The market's prior pricing already assumed a successful ramp; these results do little to confirm that assumption.

Implication

For investors, the Q3 release underscores that the equity story still hinges on unproven plant performance rather than current earnings. Without first shipment or throughput data, the stock's high valuation remains vulnerable to disappointment. The upcoming debt service schedule and potential covenant issues could force another amendment, which would signal unresolved financing stress. Conversely, any disclosure of commercial production or successful deliveries would materially de-risk the thesis. Until then, position sizing should be conservative, and investors should monitor monthly or quarterly KPIs from Sangdong rather than narrative language.

Thesis delta

The thesis remains unchanged following the Q3 report. No new evidence has emerged to shift the balance of risks: first Sangdong shipment, recovery rates, and debt service normalization are still missing. The WAIT rating and conviction level remain appropriate until these proof points are disclosed.